5. Oh DY et al. 56P-Updated overall survival from the Phase 3 TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in patients with advanced biliary tract cancer. ESMO 2022. 6. Arndt Vogel et al. Regional...
1.Oh DY, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1....
1. Oh DY, et al. Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in advanced biliary tract cancer (aBTC)2024 ESMO ASIA 135P. 2. Oh DY, He AR, Bouattour M, et al. Durvalumab or plac...
1、Oh DY, He AR, Qin S, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Évid. 2022;1. 2、Do-Youn Oh, et al. 2022 ESMO Asia Congress. Abstract 78P. 3、Arndt Vogel et al. Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalum...
[7] J.W. Valle, et al. 68O - Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). ESMO Asia Congress 2022. Annals of Oncology (2022) 33 (suppl...
Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).doi:10.1200/JCO.2022.40.16_suppl.407563334075#Background:TOPAZ-1 (NCT03875235) is a randomized, double-blind, global, Phase 3 study ...
3. Aiwu Ruth He, et al. 86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study. ESMO Asia Congress 2022. nnals of Oncology (2022) 33 (suppl_9): S1454-S148...
1625#Background:In the TOPAZ-1 study (NCT03875235), durvalumab + gemcitabine and cisplatin (D+GC) significantly improved overall survival (OS) versus placebo + GC (P+GC) in participants (pts) with advanced biliary tract cancer. Updated results have shown a clinically meaningful long-term OS ...
4. Takuji Okusaka, et al. 93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study. ESMO Asia Congress 2022. Annals of Oncology (2022) 33 (suppl_9): S1454-S1484. 10.1...
5.Lorenzo Antonuzzo, et al. 91P - Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin...